About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry ...

HAYWARD, Calif., July 10, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity. Read more here.

Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer PRISM-1, the ongoing registrational, Phase 3 study evaluating quemliclustat plus chemotherapy as a first ...

About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer.

By Freddy Sebastian Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation.

Arcus Biosciences (NYSE:RCUS) presented its corporate update on February 25, 2025, showcasing its oncology pipeline and development strategy. The presentation comes at a challenging time for the ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity. Read more here.

HAYWARD, Calif., July 09, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a biotechnology company with a strong balance sheet showing more cash than debt according to InvestingPro data, announced Thursday that its ...

On June 1, Arcus Biosciences presented the first data for casdatifan plus cabozantinib in oral metastatic kidney cancer, which showed a confirmed response.